Back to top
more

Arrowhead Pharmaceuticals (ARWR)

(Delayed Data from NSDQ)

$22.12 USD

22.12
617,025

+0.25 (1.14%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $22.12 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Fiscal Year End for Arrowhead Pharmaceuticals, Inc falls in the month of September.

All items in Millions except Per Share data.

9/30/2023 9/30/2022 9/30/2021 9/30/2020 9/30/2019
Assets          
Cash & Equivalents 404 376 368 315 259
Receivables 0 1 10 1 1
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 16 27 7 6 6
Total Current Assets 420 405 385 322 265
Net Property & Equipment 290 110 49 31 23
Investments & Advances 0 106 246 137 44
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 10 12 14 15 17
Deposits & Other Assets 0 0 0 0 0
Total Assets 766 692 710 523 350
Liabilities & Shareholders Equity 9/30/2023 9/30/2022 9/30/2021 9/30/2020 9/30/2019
Notes Payable 0 0 0 0 0
Accounts Payable 36 3 9 7 8
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 58 59 24 13 11
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 1 74 111 19 78
Total Current Liabilities 105 139 147 41 97
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 56 132 0 9
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 268 0 0 0 0
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 478 274 301 61 106
Shareholders Equity 9/30/2023 9/30/2022 9/30/2021 9/30/2020 9/30/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 1,300 1,219 1,053 965 664
Retained Earnings -1,026 -821 -645 -504 -419
Other Equity 13 20 0 0 -1
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 287 418 409 462 244
Total Liabilities & Shareholder's Equity 766 692 710 523 350
Total Common Equity 287 418 409 462 244
Shares Outstanding 107.10 105.80 104.20 102.20 94.80
Book Value Per Share 2.68 3.95 3.92 4.52 2.57

Fiscal Year End for Arrowhead Pharmaceuticals, Inc falls in the month of September.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 220 404 452 481
Receivables NA 0 0 1 69
Notes Receivable NA 0 0 0 0
Inventories NA 0 0 0 0
Other Current Assets NA 18 16 17 24
Total Current Assets NA 238 420 470 575
Net Property & Equipment NA 333 290 231 185
Investments & Advances NA 0 0 43 79
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 10 10 11 11
Deposits & Other Assets NA 0 0 0 0
Total Assets NA 626 766 796 891
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 4 36 8 10
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 55 58 43 45
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 0 1 17 30
Total Current Liabilities NA 64 105 70 87
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 0 0 0 1
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 0 0 0 0
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 268 264 258
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 453 478 414 426
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 1,320 1,300 1,281 1,260
Retained Earnings NA -1,159 -1,026 -916 -813
Other Equity NA 12 13 17 18
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 174 287 382 465
Total Liabilities & Shareholder's Equity NA 626 766 796 891
Total Common Equity 0 174 287 382 465
Shares Outstanding 123.90 123.10 107.10 106.90 106.90
Book Value Per Share 0.00 1.41 2.68 3.57 4.35